Omega-3 trials in critical illness report shorter ventilation and hospital stays
A review of randomized trials found shorter ventilation and hospital stays, alongside changes in oxygenation and inflammatory markers; the comparison treatments were not described.
Based on the published abstract. The full paper may contain additional methods, results and limitations.
The 30-second takeaway
The pooled trials reported shorter periods of mechanical ventilation and shorter hospital stays with omega-3 treatment in critically ill adults. The review also found changes in breathing and inflammatory markers. These results concern treatment during critical illness; they do not establish benefits from routine supplements for people outside that setting.
The abstract omits treatment doses, control regimens, treatment duration, and adverse-event findings. It also does not report mortality, so shorter ventilation or hospital stays cannot be interpreted as evidence of improved survival.
Several kinds of outcomes
The review combined trials using enteral or parenteral omega-3 delivery. Researchers assessed fatty acid levels, inflammatory and immune markers, breathing-related measures, and clinical outcomes, including how long patients needed mechanical ventilation.
Clinical outcomes and markers
Blood oxygenation and several laboratory markers improved in the pooled results. These measurements describe different aspects of critical illness, while ventilation duration and hospital stay describe care needs; improvement in one does not guarantee improvement in every outcome.
The original publication
Omega-3 Fatty Acids Supplementation Improves Pulmonary Function and Clinical Outcomes in Critically Ill Patients: a Meta-Analysis.
Wu MY, Wang X, Cai JZ et al.
J Nutr · 2026
- PubMed ID
- 41506327
- Record checked
AI-assisted research and writing. This explains one selected publication; it is not a complete review of everything known. Our approach.
One more question, understood.
Keep track of the research you’ve explored.